According to a recent LinkedIn post from SpinaFX Medical Inc, the company saw strong engagement at its workshop during the ASSR 2026 meeting in New Orleans. The session reportedly focused on image-guided intra-discal oxygen ozone injection for treating contained herniated discs, including hands-on training in C-arm guided needle placement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post indicates that participants also discussed clinical evidence, patient selection, follow-up, and SpinaFX’s planned pivotal clinical trial. For investors, this suggests the company is moving toward a more advanced clinical development phase, which could be a key milestone for eventual regulatory review and commercialization prospects.
By highlighting clinician education and interaction with key opinion leaders, the workshop activity may help build clinical awareness and future adoption potential for the company’s minimally invasive back pain therapy. If the planned pivotal trial proceeds successfully, SpinaFX could strengthen its positioning in the image-guided spine treatment segment and potentially enhance its valuation in the MedTech space.